THE DEAL, AT A GLANCE
From the announcementThor Therapeutics
01What it doesTHOR Therapeutics is led by Minho Shong, MD/PhD (Founder & CEO, KAIST) - a lead researcher in GDF15-GFRAL biology and endocrinology.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Minho Shong, MD/PhD (Founder & CEO, KAIST), Alteogen as a strategic investorFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedThor Therapeutics raised Series A, announced 2026-11-03From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Thor Therapeutics · Financing Record
Explore source-linked visual explanations for Thor Therapeutics. Unsupported claims are withheld while source review continues.
Record 15242 · Recorded date: 2026-11-03
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →